Breath test device and method
There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.
1. A method for non-invasively evaluating portal hypertension in a subject, comprising:
administering to a subject an isotope labeled methacetin or a salt or a derivative thereof comprising carbon-13, carbon-14, oxygen-18 or any combination thereof;
continuously collecting and analyzing, using a CO 2 sensor, changes in time of a level of a metabolic product of the labeled methacetin or the salt or the derivative thereof in multiple samples of the subject's breath;
receiving, in real-time, data indicative of magnitude of metabolization, percentage dose recovery (PDR), and cumulative PDR (CPDR);
deriving, from the data, PDR peak time, PDR height or physiological noise;
evaluating, via a processor, the portal hypertension based on an analysis of the derived PDR peak time, PDR height or physiological noise; and
outputting an indication of the evaluated portal hypertension in the subject.
2. The method of claim 1 , further comprising following-up on the portal hypertension after a predetermined period of time based on the isotope labeled methacetin breath test.
3. The method of claim 2 , wherein the predetermined period of time is between 0.5 minute and 4 hours.
4. The method of claim 1 , further comprising computing an output indication related to the evaluated portal hypertension.
5. The method of claim 1 , further comprising receiving a demographic parameter of the subject, wherein evaluating the portal hypertension is further based on the demographic parameter.
6. The method of claim 5 , wherein the demographic parameter comprises height, weight, age, gender, smoking habits, disease etiology, known information about complications, or any combination thereof.
7. A device for non-invasively evaluating portal hypertension, the device comprising:
a CO 2 sensor adapted to sense changes over time of an isotope level of a metabolic product of labeled methacetin or a salt or a derivative thereof in a breath of a subject having been administered isotope labelled methacetin or a salt or a derivative thereof comprising carbon-13, carbon-14, oxygen-18 or any combination thereof; and
a processor configured to:
receive, in real-time, data indicative of percentage dose recovery (PDR) and cumulative PDR (CPDR)
derive, from the data, PDR peak time, PDR height or physiological noise;
evaluate portal hypertension based on an analysis of a the derived PDR peak time, PDR height or physiological noise; and
output an indication of the evaluated portal hypertension in the subject.
8. The device of claim 7 , wherein the processor, after a predetermined period of time, is further adapted to receive follow-up data indicative of the isotope levels of the metabolic product of labeled methacetin and to derive from the follow-up data revised percentage dose recovery (PDR) value and to reevaluate portal hypertension based on the revised percentage dose recovery (PDR) value.
9. The device of claim 8 , wherein the predetermined period of time is between 0.5 minute and 4 hours.
10. The device of claim 7 , wherein said processor is further adapted to compute an output indication related to the portal hypertension.